Product Description
Apricoxib is an orally bioavailable nonsteroidal anti-inflammatory agent (NSAID) with potential antiangiogenic and antineoplastic activities. Apricoxib binds to and inhibits the enzyme cyclooxygenase-2 (COX-2), thereby inhibiting the conversion of arachidonic acid into prostaglandins. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Apricoxib)
Mechanisms of Action: Vaccine,RAS
Novel Mechanism: Yes
Modality: Vaccine
Route of Administration: Oral,Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Tragara
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Norway
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: Multiple Myeloma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| OMC04 | P2 |
Recruiting |
Multiple Myeloma |
2027-05-19 |